146 related articles for article (PubMed ID: 1763142)
21. Sight and insight: regional cerebral metabolic activity in schizophrenia visualised by positron emission tomography, and competing neurodevelopmental perspectives.
Waddington JL
Br J Psychiatry; 1990 May; 156():615-9. PubMed ID: 2095940
[No Abstract] [Full Text] [Related]
22. Correlation of qEEG with PET in schizophrenia.
Alper K; Günther W; Prichep LS; John ER; Brodie J
Neuropsychobiology; 1998; 38(1):50-6. PubMed ID: 9701722
[TBL] [Abstract][Full Text] [Related]
23. Blunted change in cerebral glucose utilization after haloperidol treatment in schizophrenic patients with prominent negative symptoms.
Wolkin A; Sanfilipo M; Duncan E; Angrist B; Wolf AP; Cooper TB; Brodie JD; Laska E; Rotrosen JP
Am J Psychiatry; 1996 Mar; 153(3):346-54. PubMed ID: 8610821
[TBL] [Abstract][Full Text] [Related]
24. Effect of a haloperidol challenge on regional brain metabolism in neuroleptic-responsive and nonresponsive schizophrenic patients.
Bartlett EJ; Brodie JD; Simkowitz P; Schlösser R; Dewey SL; Lindenmayer JP; Rusinek H; Wolkin A; Cancro R; Schiffer W
Am J Psychiatry; 1998 Mar; 155(3):337-43. PubMed ID: 9501742
[TBL] [Abstract][Full Text] [Related]
25. Cortical-striatal-thalamic circuits and brain glucose metabolic activity in 70 unmedicated male schizophrenic patients.
Siegel BV; Buchsbaum MS; Bunney WE; Gottschalk LA; Haier RJ; Lohr JB; Lottenberg S; Najafi A; Nuechterlein KH; Potkin SG
Am J Psychiatry; 1993 Sep; 150(9):1325-36. PubMed ID: 8352343
[TBL] [Abstract][Full Text] [Related]
26. Effect of attention on frontal distribution of delta activity and cerebral metabolic rate in schizophrenia.
Guich SM; Buchsbaum MS; Burgwald L; Wu J; Haier R; Asarnow R; Nuechterlein K; Potkin S
Schizophr Res; 1989; 2(6):439-48. PubMed ID: 2487185
[TBL] [Abstract][Full Text] [Related]
27. Prolactin bioassay in schizophrenia before and after neuroleptics.
Peabody CA; Warner MD; Griffin M; Boutros NN; Worsley IG; Friesen HG
Psychiatry Res; 1992 Mar; 41(3):249-55. PubMed ID: 1594711
[TBL] [Abstract][Full Text] [Related]
28. Effects of antipsychotic treatment on polysomnographic measures in schizophrenia: a replication and extension.
Maixner S; Tandon R; Eiser A; Taylor S; DeQuardo JR; Shipley J
Am J Psychiatry; 1998 Nov; 155(11):1600-2. PubMed ID: 9812125
[TBL] [Abstract][Full Text] [Related]
29. Regional cerebral blood flow in first-episode schizophrenia patients before and after antipsychotic drug treatment. Scottish Schizophrenia Research Group.
Acta Psychiatr Scand; 1998 Jun; 97(6):440-9. PubMed ID: 9669517
[TBL] [Abstract][Full Text] [Related]
30. Delayed normalization of central D2 dopamine receptor availability after discontinuation of haloperidol decanoate. Preliminary findings.
Nyberg S; Farde L; Halldin C
Arch Gen Psychiatry; 1997 Oct; 54(10):953-8. PubMed ID: 9337776
[TBL] [Abstract][Full Text] [Related]
31. Abnormal smooth pursuit eye movements in schizophrenic patients are associated with cerebral glucose metabolism in oculomotor regions.
Ross DE; Thaker GK; Holcomb HH; Cascella NG; Medoff DR; Tamminga CA
Psychiatry Res; 1995 Sep; 58(1):53-67. PubMed ID: 8539312
[TBL] [Abstract][Full Text] [Related]
32. [Effects of thiothixene on schizophrenic symptoms in a long-term therapeutic scheme. Comparative study with butyrophenone derivative].
Vianna Filho U; Muniz AF; Terra SO; Bueno JR
J Bras Psiquiatr; 1971; 20(3):193-204. PubMed ID: 5164436
[No Abstract] [Full Text] [Related]
33. Clozapine but not haloperidol Re-establishes normal task-activated rCBF patterns in schizophrenia within the anterior cingulate cortex.
Lahti AC; Holcomb HH; Weiler MA; Medoff DR; Frey KN; Hardin M; Tamminga CA
Neuropsychopharmacology; 2004 Jan; 29(1):171-8. PubMed ID: 14520337
[TBL] [Abstract][Full Text] [Related]
34. Stability of positive and negative symptom constructs during neuroleptic treatment in schizophrenia.
Goldman RS; Tandon R; Liberzon I; Goodson J; Greden JF
Psychopathology; 1991; 24(4):247-52. PubMed ID: 1754657
[TBL] [Abstract][Full Text] [Related]
35. Occupancy of dopamine D(1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol.
Reimold M; Solbach C; Noda S; Schaefer JE; Bartels M; Beneke M; Machulla HJ; Bares R; Glaser T; Wormstall H
Psychopharmacology (Berl); 2007 Feb; 190(2):241-9. PubMed ID: 17111172
[TBL] [Abstract][Full Text] [Related]
36. Plasma concentrations of thiothixene and clinical response in treatment-resistant schizophrenics.
Hollister LE; Lombrozo L; Huang CC
Int Clin Psychopharmacol; 1987 Jan; 2(1):77-82. PubMed ID: 3312399
[TBL] [Abstract][Full Text] [Related]
37. Effect of haloperidol dose on iodine-123-IBZM brain SPECT imaging in schizophrenic patients.
Vallabhajosula S; Hirschowitz J; Machac J
J Nucl Med; 1997 Feb; 38(2):203-7. PubMed ID: 9025736
[TBL] [Abstract][Full Text] [Related]
38. Regional brain glucose metabolism: correlations to biochemical measures and anxiety in patients with schizophrenia.
Wik G; Wiesel FA
Psychiatry Res; 1991 Oct; 40(2):101-14. PubMed ID: 1722339
[TBL] [Abstract][Full Text] [Related]
39. Stability of resting deoxyglucose metabolic values in PET studies of schizophrenia.
Bartlett EJ; Barouche F; Brodie JD; Wolkin A; Angrist B; Rotrosen J; Wolf AP
Psychiatry Res; 1991 May; 40(1):11-20. PubMed ID: 1946838
[TBL] [Abstract][Full Text] [Related]
40. Response to antipsychotic medication: the doctor's and the consumer's view.
Van Putten T; May PR; Marder SR
Am J Psychiatry; 1984 Jan; 141(1):16-9. PubMed ID: 6691455
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
